Karyopharm Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $37,929 | $30,015 | $30,542 | $38,783 |
Gross Profit | 36,878 | 28,714 | 29,211 | 37,483 |
EBITDA | -24,387 | -12,354 | -19,604 | -20,576 |
EBIT | -24,465 | -12,432 | -19,685 | -20,659 |
Net Income | -37,252 | -23,462 | -30,780 | -32,072 |
Net Change In Cash | 37,929 | 30,015 | 30,542 | 38,783 |
Free Cash Flow | -18,697 | -38,984 | -25,757 | -19,453 |
Cash | 38,725 | 38,783 | 62,476 | 72,828 |
Basic Shares | 8,620 | 8,470 | 8,392 | 8,333 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $145,237 | $146,033 | $157,074 | $209,819 |
Gross Profit | 139,230 | 141,091 | 151,861 | 206,417 |
EBITDA | -38,603 | -118,423 | -139,305 | -96,985 |
EBIT | -38,943 | -118,953 | -139,926 | -97,774 |
Net Income | -76,422 | -143,099 | -165,291 | -124,088 |
Net Change In Cash | 145,237 | 146,033 | 157,074 | 209,819 |
Cost of Revenue | -60,072 | 108,372 | ||
Free Cash Flow | -127,628 | -92,723 | -149,672 | -112,828 |
Cash | 62,476 | 52,231 | 135,188 | 190,459 |
Basic Shares | 8,124 | 7,614 | 5,458 | 5,014 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$4.07 |
2025-03-31 | -$2.77 |
2024-12-31 | -$3.60 |
2024-09-30 | -$3.90 |
